Aeglea BioTherapeutics Provides AEB1102 Program and Corporate Update
May 23, 2017 12:09 pm UTC| Business
--Announces three single agent expansion arms for AEB1102 solid tumor trials-- --Provides update on AEB1102 program in Arginase 1 Deficiency-- --Company names Aaron Schuchart as chief business officer-- AUSTIN, Texas,...
May 23, 2017 12:08 pm UTC| Business
AUSTIN, Texas, May 23, 2017 -- Propanc Biopharma Inc.(OTCQB:PPCH)("Propanc Biopharma" or "the Company"), a clinical stage biopharmaceutical company focusing on development of new and proprietary treatments for cancer...
May 23, 2017 12:08 pm UTC| Business
AUSTIN, Texas, May 23, 2017 -- Propanc Biopharma Inc.(OTCQB:PPCH)("Propanc Biopharma" or "the Company"), a clinical stage biopharmaceutical company focusing on development of new and proprietary treatments for cancer...
May 23, 2017 12:08 pm UTC| Business
AUSTIN, Texas, May 23, 2017 -- Propanc Biopharma Inc.(OTCQB:PPCH)("Propanc Biopharma" or "the Company"), a clinical stage biopharmaceutical company focusing on development of new and proprietary treatments for cancer...
May 23, 2017 12:08 pm UTC| Business
AUSTIN, Texas, May 23, 2017 -- Propanc Biopharma Inc.(OTCQB:PPCH)("Propanc Biopharma" or "the Company"), a clinical stage biopharmaceutical company focusing on development of new and proprietary treatments for cancer...
May 23, 2017 12:08 pm UTC| Business
AUSTIN, Texas, May 23, 2017 -- Propanc Biopharma Inc.(OTCQB:PPCH)("Propanc Biopharma" or "the Company"), a clinical stage biopharmaceutical company focusing on development of new and proprietary treatments for cancer...
May 23, 2017 12:08 pm UTC| Business
AUSTIN, Texas, May 23, 2017 -- Propanc Biopharma Inc.(OTCQB:PPCH)("Propanc Biopharma" or "the Company"), a clinical stage biopharmaceutical company focusing on development of new and proprietary treatments for cancer...